Sugi Predict

Sugi Predict / Compounds / R-348

R-348

R-348

SCHEMBL29610478

C#CCOc1ccc(Nc2nc(Nc3ccc(C)c(S(=O)(=O)NC(=O)CC)c3)ncc2F)cc1.C[N+](C)(C)CCO

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

JAK3SYK

The experimentally established mechanism targets of R-348. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK known ✓ P43405 15/20 0.55
▸ JAK3 known ✓ P52333 2/20 0.55
▸ EGFR P00533 5/20 0.55
▸ JAK2 O60674 4/20 0.55
▸ ITK Q08881 4/20 0.55
▸ PLK4 O00444 2/20 0.55
▸ AURKA O14965 2/20 0.55
▸ PDPK1 O15530 2/20 0.55
▸ DAPK3 O43293 2/20 0.55
▸ MAP4K4 O95819 2/20 0.55
▸ PAK4 O96013 2/20 0.55
▸ CHEK2 O96017 2/20 0.55
▸ ERBB2 P04626 2/20 0.55
▸ NTRK1 P04629 2/20 0.55
▸ PRKCG P05129 2/20 0.55
▸ INSR P06213 2/20 0.55
▸ LCK P06239 2/20 0.55
▸ FYN P06241 2/20 0.55
▸ CDK1 P06493 2/20 0.55
▸ CSF1R P07333 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
R-348 SCHEMBL1275818 1.00 SYK (0.55) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL29609827 0.94 SYK (0.61) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL1275805 0.93 SYK (0.62) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL29609719 0.93 SYK (0.62) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL1276394 0.93 SYK (0.61) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL29609591 0.93 SYK (0.61) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL29610172 0.93 SYK (0.61) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL1276450 0.93 SYK (0.61) SYKEGFRJAK2ITKPLK4
R-348 SCHEMBL1276397 0.93 SYK (0.61) SYKEGFRJAK2ITKPLK4
SCHEMBL5014360 0.88 SYK (0.59) SYKEGFRJAK2ITKPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667611-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2023-06-06 — — US disclosed
US-20220249475-A1 COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME RIGEL PHARMACEUTICALS, INC. (US) 2022-08-11 — — US disclosed
CN-114698370-A Compounds and methods for treating cytokine release syndrome 里格尔药品股份有限公司 2022-07-01 — — CN disclosed
EP-4009974-A1 COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME Rigel Pharmaceuticals, Inc. (US) 2022-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667611-B2 Compositions and methods for inhibition of the JAK pathway JAK3, JAK2, JAK1 SYK 62/4885JAK3 1/4885EGFR 529/4885
US-20220249475-A1 COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME IRAK1, IRAK3, IRAK2 SYK 93/4885JAK3 12/4885EGFR 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.